Literature DB >> 15526120

Resectable hilar cholangiocarcinoma: surgical treatment and long-term outcome.

Michael I D'Angelica1, William R Jarnagin, Leslie H Blumgart.   

Abstract

Unresected hilar cholangiocarcinoma has a dismal prognosis, but advances in staging and surgical techniques have given well-selected patients a chance of long-term survival if curative resection is possible. This review summarizes the state of the art in diagnosis, treatment, and outcome for patients with biliary obstruction at the hilus of the liver.

Entities:  

Mesh：

Year:  2004        PMID： 15526120     DOI： 10.1007/s00595-004-2832-3

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.549


  15 in total

1.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

2.  Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors.

Authors:  Mohamed Abd ElWahab; Ayman El Nakeeb; Ehab El Hanafy; Ahmad M Sultan; Ahmed Elghawalby; Waleed Askr; Mahmoud Ali; Mohamed Abd El Gawad; Tarek Salah
Journal:  World J Gastrointest Surg       Date:  2016-06-27

Review 3.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

4.  Thermo-chemo-radiotherapy for advanced bile duct carcinoma.

Authors:  Terumi Kamisawa; Yuyang Tu; Naoto Egawa; Katsuyuki Karasawa; Tadayoshi Matsuda; Kouji Tsuruta; Atsutake Okamoto
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

Review 5.  Surgical management of proximal bile duct cancers.

Authors:  Jennifer LaFemina; William R Jarnagin
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

6.  Perioperative blood transfusion is not associated with overall survival or time to recurrence after resection of perihilar cholangiocarcinoma.

Authors:  Annemiek M Dekker; Jimme K Wiggers; Robert J Coelen; Rowan F van Golen; Marc G H Besselink; Olivier R C Busch; Joanne Verheij; Markus W Hollmann; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-01-06       Impact factor: 3.647

7.  Granular cell tumor as an unusual cause of obstruction at the hepatic hilum: report of a case.

Authors:  Rajiv Lochan; Shlokarth Balupuri; Mark K Bennett; Derek M Manas
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

8.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

9.  Improved survival following right trisectionectomy with caudate lobectomy without operative mortality: surgical treatment for hilar cholangiocarcinoma.

Authors:  Kwang Yeol Paik; Dong Wook Choi; Jun Chul Chung; Kyung Tae Kang; Sang Bum Kim
Journal:  J Gastrointest Surg       Date:  2008-03-11       Impact factor: 3.452

10.  Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.

Authors:  Kyu-Hyoung Lim; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2009-09-27       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.